Rehovot, Israel

Gilad Gefen

This inventor holds 1 USPTO granted patent. Top assignee: Yeda Research and Develpment & Co. Ltd. Active years: 2016.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gilad Gefen: Innovator in Fusion Proteins and Biomass Degradation

Introduction

Gilad Gefen is a prominent inventor based in Rehovot, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins and multi-enzyme complexes. His innovative work has implications for biomass degradation, which is crucial for sustainable energy solutions.

Latest Patents

Gilad Gefen holds a patent for "Fusion proteins comprising type-II cohesin modules, multi-enzyme complexes comprising same and uses thereof." This patent describes fusion proteins that include a type-II cohesin module, which can integrate into both native and designer cellulosomes. The invention also covers modified β-glucosidases that incorporate a type-II cohesin module and the polynucleotides encoding them. Furthermore, it details multi-enzyme complexes that utilize these fusion proteins and methods for biomass degradation.

Career Highlights

Gefen's career is marked by his role at Yeda Research and Development Co. Ltd., where he has been instrumental in advancing research in his field. His work has not only contributed to scientific knowledge but also has practical applications in biotechnology and environmental sustainability.

Collaborations

Gilad Gefen has collaborated with notable scientists such as Edward A. Bayer and Michael Anbar. These partnerships have enhanced the scope and impact of his research, leading to innovative solutions in biotechnology.

Conclusion

Gilad Gefen's contributions to the field of fusion proteins and biomass degradation highlight his role as a key innovator in biotechnology. His work continues to influence sustainable practices and advancements in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…